tgDCC-E1A

tgDCC-E1A is a gene therapy product that consists of the E1A gene (derived from Adenovirus type 5) complexed with a lipid carrier called DC-Cholesterol:DOPE to form a delivery system for intratumoral or intracavitary administration. This therapy was initially developed by AmpliPhi Biosciences Corporation (formerly known as Targeted Genetics Corporation).

The E1A gene functions as a tumor suppressor and has been shown to have potent anti-neoplastic activity through various mechanisms. It primarily acts as an antagonist to HER2 (also known as HER-2/neu), a receptor protein-tyrosine kinase that is often overexpressed in certain cancers. The therapy works by downregulating HER2/neu expression, inducing apoptosis (programmed cell death), inhibiting metastasis, and reverting tumor cells toward a differentiated epithelial phenotype.

Clinical Development

tgDCC-E1A has been evaluated in several clinical trials:

1. Phase I trials were completed by the end of 1997, including: - A dose-escalation study treating patients with recurrent breast cancer and head and neck cancer - A trial in patients with breast and ovarian cancer - A trial enrolling 12-24 patients with solid tumors to determine dosing, safety, gene transfer levels, and tumor response

2. Phase II trials included: - A multicenter study for intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma - This study enrolled 24 patients who received intratumoral injections over 8 weeks - Results showed the treatment was well-tolerated with modest tumor response: 4.2% complete response, 8.3% minor response, and 29.2% stable disease

3. Combination therapy studies: - A trial combining intraperitoneal tgDCC-E1A with intravenous paclitaxel in women with platinum-resistant ovarian cancer - Research showing E1A enhances the effects of histone deacetylase inhibitors (like SAHA) in cancer cells - Studies demonstrating E1A's ability to sensitize cancer cells to EGFR tyrosine kinase inhibitors

Mechanism and Efficacy

The E1A gene therapy works through multiple mechanisms:

• Downregulation of HER2/neu expression
• Induction of apoptosis through activation of p38
• Inhibition of metastasis by decreasing levels of miR-520h and EMT marker TWIST
• Sensitization of cancer cells to chemotherapy by stabilizing FOXO3a
• Downregulation of receptor tyrosine kinases including EGFR, HER2/neu, and AXL

In preclinical studies, tgDCC-E1A demonstrated significant anti-tumor activity in mouse models of breast and ovarian cancer, increasing long-term survival. The therapy has shown particular promise in combination with other treatments, potentially offering new options for patients with limited therapeutic alternatives.

The development status of tgDCC-E1A appears to be discontinued, as the most recent information in the search results indicates the drug's highest phase was "Discontinued Phase 2".